GlassScriptPhysician profile
Martin Mcelya
NPI 1154329746
$5,310.86
in general payments reported to CMS, 2019-2025
54 companies · $626 in 2025
The $626 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $318 · 2021: $809 · 2022: $783 · 2023: $1,527 · 2024: $789 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,441 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,441.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $684.74 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $540.84 | 2021-2023 | Qelbree |
| Novo Nordisk INC | $408.85 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Genentech USA, INC. | $299.39 | 2019-2021 | |
| Abbvie INC. | $245.37 | 2021-2022 | |
| Amarin Pharma, INC. | $219.58 | 2019-2021 | |
| Lilly USA, LLC | $187.02 | 2019-2024 | Mounjaro, Zepbound |
| Organogenesis INC. | $168.75 | 2023 | Puraply |
| Amgen INC. | $167.18 | 2024-2025 | Krystexxa, Repatha |
| Smith+Nephew, INC. | $164.44 | 2021-2025 | Grafix Pl, Stravix Pl, Uni Cp |
| Bardy Diagnostics, INC. | $159.08 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $142.39 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $131.64 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $115.42 | 2023-2025 | Nuzyra, Xhance |
| Vbi Vaccine (Delaware) INC. | $111.54 | 2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Mcelya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.